However, one potential limitation of this cell-based therapeutic is that IFN-γ released from activated NK cells can induce STAT-1-dependent expression of NK cell inhibitory ligands on the surface of the cancer cells being targeted for NK cell killing [21]. This evidence concerns the gene STAT1 and cancer.